LU92185I2 - Ingenane ou un dérivé (sel ou ester) de celui-ci - Google Patents

Ingenane ou un dérivé (sel ou ester) de celui-ci

Info

Publication number
LU92185I2
LU92185I2 LU92185C LU92185C LU92185I2 LU 92185 I2 LU92185 I2 LU 92185I2 LU 92185 C LU92185 C LU 92185C LU 92185 C LU92185 C LU 92185C LU 92185 I2 LU92185 I2 LU 92185I2
Authority
LU
Luxembourg
Prior art keywords
compounds
euphorbia
jatrophanes
plants
compound
Prior art date
Application number
LU92185C
Other languages
English (en)
French (fr)
Original Assignee
Leo Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3802927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92185(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Lab Ltd filed Critical Leo Lab Ltd
Publication of LU92185I2 publication Critical patent/LU92185I2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LU92185C 1997-08-19 2013-04-23 Ingenane ou un dérivé (sel ou ester) de celui-ci LU92185I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO8640A AUPO864097A0 (en) 1997-08-19 1997-08-19 Anti-cancer compounds

Publications (1)

Publication Number Publication Date
LU92185I2 true LU92185I2 (fr) 2014-04-23

Family

ID=3802927

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92185C LU92185I2 (fr) 1997-08-19 2013-04-23 Ingenane ou un dérivé (sel ou ester) de celui-ci

Country Status (17)

Country Link
US (4) US6432452B1 (enExample)
EP (1) EP1015413B1 (enExample)
JP (3) JP2001515059A (enExample)
CN (1) CN1266421B (enExample)
AT (1) ATE397580T1 (enExample)
AU (1) AUPO864097A0 (enExample)
BE (1) BE2013C026I2 (enExample)
BR (1) BR9811327A (enExample)
CA (1) CA2301082C (enExample)
CY (2) CY1108303T1 (enExample)
DE (1) DE69839586D1 (enExample)
DK (1) DK1015413T3 (enExample)
ES (1) ES2308810T3 (enExample)
HU (2) HU228862B1 (enExample)
LU (1) LU92185I2 (enExample)
PT (1) PT1015413E (enExample)
WO (1) WO1999008994A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO864097A0 (en) * 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US7078434B1 (en) * 1999-08-12 2006-07-18 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Use of Ginkgo extract
AU748542B2 (en) * 2000-06-07 2002-06-06 Leo Laboratories Limited Therapeutic agents - III
AUPQ801700A0 (en) * 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
AUPQ923100A0 (en) 2000-08-07 2000-08-31 Peplin Research Pty Ltd Treatment of prostate cancer
US6923993B2 (en) * 2001-12-12 2005-08-02 Nicholas J. Donato Process of isolating extract from the Euphorbia obesa plant and methods for using the same
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP2272951B1 (en) 2003-10-14 2014-07-23 Baxter International Inc. Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
AU2005214979B2 (en) * 2004-02-17 2009-09-10 The Uab Research Foundation Cytotoxin compound and method of isolation
US20070155685A1 (en) * 2004-02-27 2007-07-05 Karl-Hermann Schlingensiepen Pharmaceutical composition
DE102004044428A1 (de) * 2004-09-14 2006-03-30 Toximed Gmbh Verfahren und pharmazeutischer Wirkstoff zur Bekämpfung von Plasmodien
AU2005316185B2 (en) * 2004-12-13 2012-04-12 Leo Laboratories Limited Treatment of solid cancers
WO2006063382A1 (en) * 2004-12-13 2006-06-22 Peplin Research Pty Ltd Treatment of solid cancers
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2006134609A2 (en) * 2005-06-16 2006-12-21 Mmi Corporation Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof
US7655620B2 (en) * 2005-07-07 2010-02-02 Cancure Laboratories, Llc Use of one or more metal carriers to selectively kill mammalian cells
CA2615105A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
US9597311B2 (en) * 2005-09-27 2017-03-21 Robert Benson Aylor Suppression and prevention of tumors
CN101360506A (zh) * 2005-11-25 2009-02-04 派普林研究股份有限公司 创伤愈合的方法
WO2007065925A2 (de) * 2005-12-07 2007-06-14 Toximed Gmbh Zusammensetzung zur behandlung von melanomen und hautunreinheiten sowie kosmetisches hautpflegemittel
GB0525680D0 (en) 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
EP1976835A2 (en) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080069809A1 (en) * 2006-04-20 2008-03-20 Ogbourne Steven M Compositions and methods for the diagnosis and treatment of cancer
US20080207738A1 (en) * 2007-02-28 2008-08-28 Cancure Laboratories, Llc Drug combinations to treat drug resistant tumors
TWI389699B (zh) * 2009-02-13 2013-03-21 高雄醫學大學 用於誘導細胞凋亡之樟芝子實體乙醇萃取物及其製備方法
PL2395993T3 (pl) * 2009-02-13 2017-10-31 Leo Laboratories Ltd Zabieg na skórę
CN102844294A (zh) 2010-04-16 2012-12-26 利奥制药有限公司 结晶巨大戟二萜醇甲基丁烯酸酯
WO2011139172A1 (en) * 2010-05-06 2011-11-10 Goran Milosavljevic Diterpene compounds with antineoplastic activities and pharmaceutical compositions comprising same
JP6116481B2 (ja) * 2010-10-25 2017-04-19 ニーキ ファーマ インコーポレイテッド 神経内分泌腫瘍を治療する方法
WO2012080466A2 (en) 2010-12-17 2012-06-21 Leo Pharma A/S Ingenols for treating seborrheic keratosis
EP2655311A1 (en) 2010-12-22 2013-10-30 Leo Laboratories Limited Ingenol-3-acylates i
TWI548616B (zh) 2010-12-22 2016-09-11 理奧實驗有限公司 巨大戟萜醇－３－醯化物iii及巨大戟萜醇－３－胺基甲酸酯化物
JP5911508B2 (ja) 2010-12-22 2016-04-27 レオ・ラボラトリーズ・リミテッドＬｅｏ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｉｍｉｔｅｄ ３−アシル−インゲノールｉｉ
US8858953B2 (en) 2011-05-09 2014-10-14 Yu-Hwa Peter Sheng Herbal composition for treating cancer
WO2012176015A1 (en) 2011-06-24 2012-12-27 Leo Pharma A/S Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate
KR101374760B1 (ko) * 2011-10-26 2014-03-17 한국생명공학연구원 포볼 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
US9422309B2 (en) 2012-06-26 2016-08-23 Leo Laboratories Limited 3-O-heteroaryl-ingenol
CN103655674A (zh) * 2012-09-11 2014-03-26 清华大学深圳研究生院 乳浆大戟提取物及其制备方法和应用
KR101578404B1 (ko) 2014-03-18 2015-12-18 원광대학교 산학협력단 대극속 식물 추출물 또는 분획물을 유효성분으로 포함하는 암 예방 또는 치료용 조성물
US9948261B2 (en) * 2014-11-20 2018-04-17 Tymphany Hk Limited Method and apparatus to equalize acoustic response of a speaker system using multi-rate FIR and all-pass IIR filters
CN106916580A (zh) * 2015-10-01 2017-07-04 钱秀英 一种基于生物显色技术以服务于物联网的储物箱
CN106905950A (zh) * 2015-10-01 2017-06-30 钱秀英 一种用于判断时间的生物显色剂
US12502369B2 (en) 2015-11-11 2025-12-23 K-Gen, Inc. Methods of cancer treatment
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
MY197240A (en) 2016-09-02 2023-06-07 Thailand Center Of Excellence For Life Sciences Method for preparing an extract of hevea latex and composition thereof
CN110663685B (zh) * 2019-10-23 2021-10-12 扬州大学 一种介孔二氧化硅负载ppte的纳米农药制剂
CN112441924B (zh) * 2020-12-11 2024-05-03 浙江工业大学 巨大戟二萜化合物及其提取方法与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2902506A1 (de) * 1979-01-23 1980-07-24 Deutsches Krebsforsch Verwendung von nicht oder nur gering irritierenden und/oder promovierenden diterpenalkoholen und von derivaten davon als antineoplastische mittel
JPS5813571A (ja) * 1981-07-14 1983-01-26 Sagami Chem Res Center ジヒドロフラン誘導体及びその製造方法
US4418064A (en) * 1982-09-29 1983-11-29 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone
US4560774A (en) 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
US5886019A (en) 1986-06-11 1999-03-23 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. F.
US5145842A (en) 1986-06-11 1992-09-08 Alder Research Center Limited Partnership Protein kinase c. modulators. d.
US5643948A (en) 1986-06-11 1997-07-01 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. K.
US5716968A (en) 1986-06-11 1998-02-10 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. H.
US5891906A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Polyacetate-derived phorboids having anti-inflammatory and other uses
US5750568A (en) 1986-06-11 1998-05-12 Procyon Pharmaceuticals, Inc. Protein kinase C Modulators. L.
US5886017A (en) 1986-06-11 1999-03-23 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. E.
IL82811A0 (en) 1986-06-11 1987-12-20 Alder Res Center Corp Anti-inflammatory compositions containing methanol derivatives and novel compounds contained therein
US5891870A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Protein kinase C modulators Q
DE3805965A1 (de) 1988-02-25 1989-09-07 Tamas Geb Szenasi Eszter Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe
DE4102054A1 (de) 1991-01-24 1992-07-30 Geb Szenasi Tamas Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe
CN1047084C (zh) 1993-03-30 1999-12-08 刘振宪 人参口服液及其制造方法
US6593371B1 (en) 1993-05-19 2003-07-15 Jeff J. Staggs Treatment for wart and related disorders
CN1048164C (zh) 1993-08-24 2000-01-12 吴雪姣 复方菝葜口服液
JP2913451B2 (ja) 1994-06-22 1999-06-28 株式会社イナックス 防水パンの高さ調整構造
JPH08245505A (ja) 1994-09-09 1996-09-24 Tosoh Corp ジテルペン誘導体、その製造法及びそれを有効成分として含有する抗腫瘍剤
JPH08176002A (ja) * 1994-12-27 1996-07-09 Kao Corp 細胞接着抑制剤
CN1070372C (zh) 1995-02-15 2001-09-05 赵国强 强力抗癌膏及其制造方法
WO1997015575A1 (en) 1995-10-27 1997-05-01 Procyon Pharmaceuticals, Inc. Protein kinase c modulators. y.
CN1058620C (zh) * 1995-11-12 2000-11-22 卢颖 一种治疗癌症的外用中成药及配备生产工艺
JPH08268961A (ja) * 1996-02-28 1996-10-15 Procyon Pharmaceut Inc 抗炎症組成物
US5932613A (en) * 1996-07-03 1999-08-03 Millennium Pharmaceuticals, Inc. Anticancer agents
AUPO864097A0 (en) * 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
JP2001139468A (ja) 1999-11-11 2001-05-22 Lead Chemical Co Ltd 抗ウイルス作用を有するホルボール誘導体
US6444555B2 (en) * 1999-12-07 2002-09-03 Advanced Micro Devices, Inc. Method for establishing ultra-thin gate insulator using anneal in ammonia
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
AUPQ923100A0 (en) 2000-08-07 2000-08-31 Peplin Research Pty Ltd Treatment of prostate cancer
US20030185168A1 (en) * 2002-03-28 2003-10-02 Yu-Wei Tung Topology of frequency converting blocks of wireless lan access point

Also Published As

Publication number Publication date
EP1015413A1 (en) 2000-07-05
HUS1300063I1 (hu) 2019-11-28
AU8721798A (en) 1999-03-08
AUPO864097A0 (en) 1997-09-11
ATE397580T1 (de) 2008-06-15
US20050003031A1 (en) 2005-01-06
US6844013B2 (en) 2005-01-18
JP2015007130A (ja) 2015-01-15
CA2301082C (en) 2009-02-03
CY2013020I1 (el) 2019-11-27
EP1015413A4 (en) 2004-01-28
PT1015413E (pt) 2008-09-15
HUP0004262A1 (hu) 2001-08-28
CN1266421B (zh) 2014-06-18
US6787161B2 (en) 2004-09-07
ES2308810T3 (es) 2008-12-01
US6432452B1 (en) 2002-08-13
US7410656B2 (en) 2008-08-12
CY2013020I2 (el) 2019-11-27
EP1015413B1 (en) 2008-06-04
BR9811327A (pt) 2000-09-19
US20020076457A1 (en) 2002-06-20
BE2013C026I2 (en) 2018-06-05
DK1015413T3 (da) 2008-09-22
CY1108303T1 (el) 2014-02-12
CN1266421A (zh) 2000-09-13
US20010051644A1 (en) 2001-12-13
JP2012031212A (ja) 2012-02-16
WO1999008994A1 (en) 1999-02-25
DE69839586D1 (de) 2008-07-17
HU228862B1 (en) 2013-06-28
JP2001515059A (ja) 2001-09-18
AU736230B2 (en) 2001-07-26
CA2301082A1 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
EP1015413A4 (en) ANTI CANCER COMPOUNDS
GEP20012388B (en) Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates
FI914723A0 (fi) 17b-substituerade 4-aza-5a-androstan -3-jon-derivat och foerfarande foer framstaellning av desamma.
NO164092C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive hydroksamsyrebaserte kollagenaseinhibitorer.
ATE210440T1 (de) Behandlung von tumoren mit verbindungen mit einer rxr-retinoid agonistische wirkung
TR199902606T2 (xx) Farnesil transferaz� engelleyici kinazolinonlar.
MX9300662A (es) Derivados fosfonooxi y carbonato de taxol
WO1998051294A3 (en) Method and composition for treating cancers
PT981341E (pt) Uso de derivados de acido betulinico para o tratamento e prevencao de melanona
PL332509A1 (en) Beta-sulphonyl-hydroxamic acids as inhibitors of intercellular substance metaloproteinases
SE8902326D0 (sv) Karboxamidfoereningar, foerfaranden foer framstaellning av dem och farmceutiska kompositioner som innehaaller dem
CA2396865A1 (en) Farnesyl protein transferase inhibitors for treating breast cancer
DK0796622T3 (da) Anvendelse af en gonadotropin-frigivende hormonanalog eller efterligning deraf til fremstilling af et farmaceutisk præparat som et supplement til den invasive behandling af carcinomer
CA2238283A1 (en) Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
AU3052799A (en) Pharmaceutical compositions comprising erythropoietin for treatment of cancer
KR950700412A (ko) 종양성장을 저해시키는 단백질 성분물(protein compound capable of inhibiting tumoral growth)
MX9306680A (es) Compuestos de piridil-, quinolil- y naftilmetoxifenilo que inhiben la enzima lipoxigenasa y composiciones farmaceuticas que los contienen.
GB9907571D0 (en) Compounds
IL101245A0 (en) Pharmaceutical compositions for the treatment of prostatic cancer
ATE91237T1 (de) Kombinationen von nekrose-tumor-faktoren und entzuendungshemmenden mitteln fuer die behandlung von boesartigen und nicht boesartigen erkrankungen.
MX9702037A (es) Metodo para minimizar el efecto uterotrofico de tamoxifeno y analogos de tamoxifeno.
NO932843D0 (no) Farmasoeytiske preparater
DE69218200D1 (de) Behandlung von leberkrebs
PT972521E (pt) Composicao farmaceutica contendo estimuladores de interferao gama
DE69424008D1 (de) Hemmung von traumainduziertem tumorwachstum